Learning Materials
AIM-LO (ASCVD Identification and Management of Lipid Lowering Therapy) is a Canadian initiative to educate, encourage and motivate community-based specialists to ensure patients with dyslipidemia who are at high risk of cardiovascular events are optimized on lipid-lowering therapy as recommended by the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines.
Watch the videos below to learn from the experts about the guidelines, LDL-cholesterol, therapeutic management of ASCVD, and more.
Video Library
Overview of 2021 CCS Dyslipidemia Guidelines: Focus on Secondary Prevention
LDL-C: Lower for Longer is Better
Non-HDL Cholesterol: Evolving Evidence Leads to a Novel Strategy
Key Tips to Maximize Therapeutic Access for Your Patients
Statins + Ezetimibe
Icosapent ethyl (IPE)
PCSK9 Inhibition (mAbs and siRNA): Classes & Mechanisms of Action
PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data
